{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:17:11Z","timestamp":1767889031260,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,5,23]],"date-time":"2015-05-23T00:00:00Z","timestamp":1432339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ACTSI KL2-Mentored Clinical and Translational Research Program (EOS)","award":["KL2TR000455"],"award-info":[{"award-number":["KL2TR000455"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Genzyme Corporation"},{"name":"Lysosomal Disease Network"},{"name":"NIH","award":["U54NS065768"],"award-info":[{"award-number":["U54NS065768"]}]},{"name":"National Center for Advancing Translational Science (NCATAS)"},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke (NINDS)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of Minnesota and Lysosomal Disease Network","award":["U54NS065768"],"award-info":[{"award-number":["U54NS065768"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ymgmr.2015.05.004","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T17:30:16Z","timestamp":1434389416000},"page":"30-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Immune tolerance strategies in siblings with infantile Pompe disease \u2014 Advantages for a preemptive approach to high-sustained antibody titers"],"prefix":"10.1016","volume":"4","author":[{"given":"Elizabeth O.","family":"Stenger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoheb","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Gambello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2015.05.004_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0015","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0045","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0050","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0060","unstructured":"Myozyme (2006) [Package Insert ]. Cambridge (MA): Genzyme Corporation."},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0065","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","article-title":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells","volume":"105","author":"Banugaria","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0080","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0090","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0095","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0100","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2353\/ajpath.2010.090468","article-title":"Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies","volume":"176","author":"Gazzerro","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/153537020623100315","article-title":"Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation","volume":"231","author":"Beehler","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0115","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/humu.20745","article-title":"Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating","volume":"29","author":"Kroos","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02238520","article-title":"Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children","volume":"12","author":"Vogel","year":"1991","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase Alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0130","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","article-title":"Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease","volume":"114","author":"Hunley","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2015.05.004_bb0135","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/ajmg.a.31936","article-title":"Sibling phenotype concordance in classical infantile Pompe disease","volume":"143A","author":"Smith","year":"2007","journal-title":"Am J Med Genet A"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426915300100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426915300100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:48:29Z","timestamp":1762001309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426915300100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":27,"alternative-id":["S2214426915300100"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2015.05.004","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune tolerance strategies in siblings with infantile Pompe disease \u2014 Advantages for a preemptive approach to high-sustained antibody titers","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2015.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}